Prelude Therapeutics Incorporated (PRLD) Research

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

Market snapshot

Symbol
PRLD
Price
$4.32
Day change
-0.69%
Market cap
$245.9M
P/E ratio
-4.58x
52-week range
0.75-5.54
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$8.00

Peer companies

  • Avalo Therapeutics, Inc. (AVTX)
  • Caribou Biosciences, Inc. (CRBU)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Eupraxia Pharmaceuticals Inc. (EPRX)
  • Foghorn Therapeutics Inc. (FHTX)
  • Immuneering Corporation (IMRX)
  • Inventiva S.A. (IVA)
  • Orchestra BioMed Holdings, Inc. (OBIO)

Recent insider activity

  • BAKER BROS. ADVISORS LP — A-Award (38000 shares) on 2026-06-09
  • Dorton Katina — A-Award (38000 shares) on 2026-06-09
  • Babler Martin — A-Award (38000 shares) on 2026-06-09
  • Bonita David P — A-Award (38000 shares) on 2026-06-09
  • Sandor Victor — A-Award (38000 shares) on 2026-06-09

Open Prelude Therapeutics Incorporated (PRLD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.